Document Status

This document has been corrected

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

10.1007/s10120-023-01419-9

Published Online: 2023-08-07

Journal: Gastric Cancer•Publisher: Springer Science and Business Media LLC

Authors: Kazuhiro Yoshida•Masahiro Takeuchi•Masashi Fujii•Mitsugu Kochi•Takeshi Sano•Wataru Ichikawa•Yasuhiro Kodera•Yoshihiro Kakeji•Yu Sunakawa

This document has been corrected

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

10.1007/s10120-023-01419-9

Published Online: 2023-08-07

Journal: Gastric Cancer

Authors: Kazuhiro Yoshida•Masahiro Takeuchi•Masashi Fujii•Mitsugu Kochi•Takeshi Sano•Wataru Ichikawa•Yasuhiro Kodera•Yoshihiro Kakeji•Yu Sunakawa

NOW

2024-06-12•Correction

Correction: Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

10.1007/s10120-024-01519-0

* information provided by CrossRef

2024-06-12•Correction

10.1007/s10120-024-01519-0

* information provided by CrossRef

2023-08-07•Published